Similar articles

• Target practice: lessons from phase III trials with bevacizumab and vatalanib in the treatment of advanced colorectal cancer.

  Los M, Roodhart JM, Voest EE. Los M, et al. Oncologist. 2007 Apr;12(4):443-50. doi: 10.1634/theoncologist.12-4-443. Oncologist. 2007. PMID: 17470687 Review.
• Biomarkers for assessment of pharmacologic activity for a vascular endothelial growth factor (VEGF) receptor inhibitor, PTK787/ZK 222584 (PTK/ZK): translation of biological activity in a mouse melanoma metastasis model to phase I studies in patients with advanced colorectal cancer with liver metastases.

  Lee L, Sharma S, Morgan B, Allegrini P, Schnell C, Brueggen J, Cozens R, Horsfield M, Guenther C, Steward WP, Drevs J, Lebwohl D, Wood J, McSheehy PM. Lee L, et al. Cancer Chemother Pharmacol. 2006 Jun;57(6):761-71. doi: 10.1007/s00280-005-0120-6. Epub 2005 Sep 20. Cancer Chemother Pharmacol. 2006. PMID: 16172907 Clinical Trial.
• Vatalanib in advanced colorectal cancer: two studies with identical results.

  Sobrero AF, Bruzzi P. Sobrero AF, et al. J Clin Oncol. 2011 May 20;29(15):1938-40. doi: 10.1200/JCO.2010.33.2429. Epub 2011 Apr 4. J Clin Oncol. 2011. PMID: 21464409 No abstract available.
• PTK/ZK (Novartis).

  Drevs J. Drevs J. IDrugs. 2003 Aug;6(8):787-94. IDrugs. 2003. PMID: 12917775 Review.
• Effect of VEGF receptor inhibitor PTK787/ZK222584 [correction of ZK222548] combined with ionizing radiation on endothelial cells and tumour growth.

  Hess C, Vuong V, Hegyi I, Riesterer O, Wood J, Fabbro D, Glanzmann C, Bodis S, Pruschy M. Hess C, et al. Br J Cancer. 2001 Dec 14;85(12):2010-6. doi: 10.1054/bjoc.2001.2166. Br J Cancer. 2001. PMID: 11747347 Free PMC article.